Type 2 Diabetes Mellitus – Personalising Management with Non-Insulin Medications

Objectives

Provide concise, evidence-based guidance for healthcare professionals in Singapore on optimising non-insulin management of type 2 diabetes mellitus, with the overarching aim of preventing or delaying diabetes-related complications and improving quality of life.[1][2]Apply an individualised, patient-centred framework that gives equal importance to glycaemic control and reducing adverse cardiovascular and renal outcomes, rather than relying solely on glycated haemoglobin reduction.[2][3]

• Individualise glycated haemoglobin targets through discussion with patients, recognising that a target of 7.0% or below is reasonable for most people but that targets should vary with age, disease duration, life expectancy, complications and other personal circumstances.[2]
• Integrate sustained lifestyle intervention as the foundation of care, including a balanced diet, healthy weight, regular physical activity, limited alcohol consumption, smoking cessation and support for mental well-being.[3]
• Personalise medicine selection according to glycaemic needs, cardiovascular and renal risk, comorbidities, overall health, treatment safety, weight effects, affordability, administration route, dosing frequency, adherence factors, and the patient’s preferences, needs and values.[4][5][6]
• Use metformin as first-line treatment for most patients alongside comprehensive lifestyle intervention, while considering alternative first-line therapy when metformin is contraindicated or not tolerated.[7]
• Reduce major adverse cardiovascular events, heart-failure hospitalisation and adverse renal outcomes by considering sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists for people with, or at high risk of, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease.[8][9]
• Strengthen self-management through education on lifestyle change, medication adherence and regular review, supported by feasible and sustainable personalised care plans.[10]

Implementation

Deliver care through shared decision-making, regular clinical review and coordinated multidisciplinary support.[11][12]Assess each patient’s glycaemic status, cardiorenal risk and overall health before selecting or adjusting treatment, then agree management goals and a plan that reflects clinical priorities and patient circumstances.[1][2][4]

• Assess cardiovascular and renal risk using relevant factors such as established cardiovascular disease, chronic kidney disease, hypertension, obesity, smoking, family history, albuminuria, age and history of acute kidney injury.[4]
• Discuss disease progression, comorbidities, prognosis, treatment options, self-management, adherence, anticipated follow-up and patient preferences, including whether treatment should prioritise glycated haemoglobin reduction, cardiorenal protection, or both.[4][11]
• Use monotherapy initially where appropriate to facilitate monitoring of treatment response and adverse effects, with review and titration suggested after about three months.[8]Consider initial dual therapy when monotherapy is unlikely to achieve the target, including when initial glycated haemoglobin is at least 1.5 percentage points above target.[8]
• Prescribe sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists independently of glycated haemoglobin level when people with established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease need cardiorenal risk reduction.[9][6]Make decisions for people without established disease individually according to risk factors.[6]
• Balance expected cardiorenal and weight benefits against hypoglycaemia risk, renal and hepatic precautions, other safety concerns, administration route, dosing frequency and affordability.[6]Recognise that sodium-glucose cotransporter 2 inhibitors have shown a larger effect on heart-failure hospitalisation and composite renal outcomes, while the observed renal benefit of glucagon-like peptide-1 receptor agonists is mainly driven by reduced macroalbuminuria.[9]
• Manage metformin gastrointestinal effects by gradually titrating the dose, advising administration with or after food, and considering an extended-release formulation where better tolerated.[7]
• Use insulin when clinically indicated, including when non-insulin medicines do not achieve glycaemic targets or symptomatic hyperglycaemia is present.[3]Introduce basal insulin first in usual practice, review concomitant medicines, and educate patients and carers on preventing and managing hypoglycaemia.[3]
• Provide relevant verbal and written education, encourage questions, explore barriers to adherence, link medicine-taking to daily routines, use reminder tools where helpful and involve family members where appropriate.[10][12]
• Connect patients with diabetes educators, dietitians, local healthy-lifestyle services and other relevant professionals, using coordinated interdisciplinary care led by the primary care clinician where appropriate.[10][12]Involve medical specialists when glycaemic control remains difficult, serious hypoglycaemia or acute metabolic complications occur, or complications require active specialist management.[12]
• Review treatment response, progress against agreed goals, hypoglycaemia and microvascular complications regularly.[4]Tailor review frequency to progress, with six-monthly review when goals are met, three-monthly review when goals are not met or are challenging, and earlier review when medicines are started, adjusted or stopped.[12]
• Monitor glycated haemoglobin, blood pressure, weight, body mass index, lipid profile, kidney parameters, smoking status, and eye and foot health, with kidney, eye and foot complication screening at least annually.[12]Share results with patients before appointments where possible to support preparation and shared decisions.[10]
• Support governance through guidance developed by an expert group spanning endocrinology, internal medicine, pharmacy, nursing, cardiology, primary care and nephrology across Singapore institutions.[13]Use the Agency for Care Effectiveness, established by the Ministry of Health, for clinical guidance, health technology assessment, healthcare education and monitoring of significant evidence changes after publication.[13][7]Review guidance usually around five years after publication, or earlier if new evidence requires substantive recommendation changes.[13]

Monitoring & Evaluation

Monitoring centres on individualised clinical review of glycaemic control, cardiorenal risk, treatment response, complications and progress against jointly agreed management goals.[2][4][11]Glycated haemoglobin targets should be individualised with the patient; a level of 7.0% or below is reasonable for most people, although more or less stringent targets may be appropriate according to age, disease duration, life expectancy and complications.[2]

• Assess cardiovascular and renal risk using relevant factors, including established cardiovascular disease, chronic kidney disease, hypertension, obesity, smoking, family history, albuminuria, age and previous acute kidney injury where relevant.[4]
• Review treatment response, HbA1c against the individual target, hypoglycaemia risk and microvascular complications, particularly after initiating or changing therapy.[4][8]
• Monitor treatment adverse effects and titrate therapy following initiation; monotherapy may facilitate assessment of both response and adverse effects, with review and titration suggested after about three months.[8]
• Undertake regular follow-up for all people with type 2 diabetes, including treatment-response assessment and complication screening.[12]Review approximately every six months when goals are met, every three months when they are unmet or difficult to achieve, and earlier when medicines are started, adjusted or stopped.[12]
• Measure HbA1c, blood pressure, weight, body mass index, lipid profile, kidney parameters and smoking status, and assess eye and foot health.[12]Conduct kidney, eye and foot screening at least annually.[12]
• Apply medicine-specific surveillance and precautions, including renal-function and safety monitoring for sodium-glucose cotransporter 2 inhibitors, and monitoring for dehydration, pancreatitis, renal impairment and retinopathy-related concerns with glucagon-like peptide-1 receptor agonists.[6]
• Share HbA1c and other relevant results with patients before appointments where feasible, explain their relevance to management goals, and use reviews to support informed shared decision-making.[10][11]
• Use cardiovascular outcome trials to evaluate the cardiovascular safety and cardiorenal effects of newer medicines, interpreting findings in light of trial purpose, eligibility criteria, endpoint definitions and relevance to the wider type 2 diabetes population.[9]

The Agency for Care Effectiveness monitors significant changes in the evidence base relevant to first-line treatment and initial dual therapy after publication.[7]Its clinical guidances are usually reviewed around five years after publication, or sooner if new evidence requires substantive recommendation changes.[13]Local resources for regular clinical review may include the Chronic Disease Management Programme and Healthier SG Care Protocols.[12]The available material does not specify a formal implementation reporting system, population surveillance programme, performance dashboard, named reporting responsibilities or wider accountability measures beyond clinical review, evidence monitoring and guidance review.[4][7][13]

Costing & Financing

Affordability and treatment cost are patient-level considerations in selecting and sustaining type 2 diabetes treatment, rather than a described programme financing framework.[4][5]Cost may affect medication adherence, and poor adherence is associated with greater use of medical resources and higher healthcare costs.[10][12]

• Consider medicine cost and affordability alongside expected glycaemic and cardiorenal benefit, weight effects, hypoglycaemia risk, safety, route of administration and dosing frequency when discussing treatment choices.[5][6]
• Use metformin as a feasible foundation for most patients where appropriate, reflecting its low cost and wide availability as well as its effectiveness, weight-neutral profile, low hypoglycaemia risk and established long-term safety record.[7]
• Recognise that extended-release metformin is more expensive than immediate-release metformin and is not currently listed for government subsidy.[7]
• Recognise that sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists are considerably more expensive than established medicine classes.[6]Consult the government subsidy list for medicines that are available through subsidy arrangements.[6]
• Address potential cost barriers to adherence through personalised discussion and practical support, while recognising that the cited local evidence reports poor adherence among 35% of people newly diagnosed with diabetes without assigning a monetary value.[10]

No explicit medicine prices, subsidy amounts, implementation budget, financing allocation, funding source, resource-mobilisation plan, funding gap or economic model is provided in the available material.[5][8][6][13]